koto_feja
- Bristol-Myers Squibb (New York Stock Exchange:BMY) has returned the rights to a preclinical cancer drug candidate, an SOS1 inhibitor, to Schrodinger (NASDAQ:SDGR).
- Schrodinger said it had submitted a development candidate and that Bristol had been conducting IND-enabling studies on it.
- the two companies They began their collaboration in 2020, which included an initial payment of $55 million from Bristol and up to $2.7 billion in milestones. An immunology target and a neurology target that are part of that agreement are not affected.
- Part of the reason Bristol (BMY) may have returned the candidate is that it obtained an SOS1 inhibitor, MRTX0902, currently in Phase 1, through its recent $4.8 billion acquisition of Mirati Therapeutics.
- SOS1 is a protein that regulates the ability of the KRAS gene to go through “on” and “off” stages. KRAS mutations are implicated in approximately one-third of cancers.
